---
schema_version: "secwatch.filing_event.v1"
accession: "0001420800-23-000003"
form_type: "8-K"
ticker: "ENOV"
cik: "0001420800"
company_name: "Enovis CORP"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:21:04.300132+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enovis Q4 net loss $0.71/sh, adj EPS $0.72; FY22 sales up 10% to $1.6B; guides FY23 adj EPS $2.15-2.30

## Summary
- Q4 net sales $409M (+2% YoY, +5% organic); Reconstructive segment organic growth 14%.
- Q4 adj EBITDA $75M (18.3% of sales), +290 bps YoY; full-year adj EBITDA margin 15.1% (+70 bps).
- FY22 net loss from continuing ops $38M ($0.25/diluted); adj EPS $2.27, up 15% YoY.
- FY23 guidance: organic revenue growth 5-6%, adj EBITDA $255-265M, adj EPS $2.15-2.30.
- Acquired Insight Medical Systems (ARVIS augmented reality) in 2022; acquisitions delivered double-digit organic growth.

## SEC filing metadata
- accession: 0001420800-23-000003
- form_type: 8-K
- ticker: ENOV
- cik: 0001420800
- company_name: Enovis CORP
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/0001420800-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/cfx-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420800-23-000003
- JSON: https://secwatch.observer/filing/0001420800-23-000003.json
- Plain text: https://secwatch.observer/filing/0001420800-23-000003.txt

## Key facts
- Earnings Releases
  Enovis CORP reported the fourth quarter ended December 31, 2022 results: revenue $409 million, net income net loss from continuing operations of $55 million, or $0.71 per diluted share, EPS $0.72.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $409 million
  - Net income: net loss from continuing operations of $55 million, or $0.71 per diluted share
  - EPS: $0.72
  - Result: reported results
  source text: • Completed first year as independent Med Tech growth company with sales growth of 10%, organic growth of 6% and EBITDA margin expansion • Grew fourth quarter sales 2% to $409 million, with 5% organic growth over the prior year quarter, and double-digit growth performance in its Reconstructive segment • Reported a fourth quarter net loss from continuing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/0001420800-23-000003-index.htm
- Earnings Releases
  Enovis CORP reported the 2022 fiscal year results: revenue $1.6 billion, net income net loss from continuing operations of $38 million, or $0.25 per diluted share, EPS $2.27. Guidance initiated.
  - Period: the 2022 fiscal year
  - Revenue: $1.6 billion
  - Net income: net loss from continuing operations of $38 million, or $0.25 per diluted share
  - EPS: $2.27
  - Guidance: initiated
  - Result: reported results
  source text: segment grew 12%, and 14% on an organic basis, and its Prevention and Recovery segment declined 2% with 1% organic growth. For the 2022 fiscal year, net sales grew 10% to $1.6 billion, with organic growth of 6%. Enovis also reported a fourth quarter operating loss of $28 million or 6.9% of sales, and adjusted EBITDA of $75 million, or 18.3% of sales, an
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420800/000142080023000003/0001420800-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.